CURRICULUM VITAE
`
`Robert J. Valuck, Ph.D., R.Ph.
`
`Business Address
`
`Home Address
`
`University of Colorado
`Skaggs School of Pharmacy and Pharmaceutical Sciences
`12850 E. Montview Boulevard, V20-1201
`Aurora, Colorado 80045
`Telephone:
`(303) 724-2890
`Fax:
`(303) 724—2627
`E—mail:
`robert.valuck@ucdenver. edu
`
`7059 S. Magnolia Circle
`Centennial, Colorado 80112
`Telephone:
`(303) 770-1828
`E—mail: robert.valuck@comcast.net
`
`EDUCATION
`
`1994
`
`1992
`
`1987
`
`Ph.D., Pharmacy (Emphasis in Pharmacy Administration)
`University of Illinois at Chicago, Chicago, Illinois
`Dissertation: The Effect of Regulatory Controls on the Quality of Psychoactive
`Drug Prescribing
`
`M.S., Pharmacy (Emphasis in Pharmacy Administration)
`University of Illinois at Chicago, Chicago, Illinois
`Thesis: Macro-level Screening Criteria to Identify Suboptimal Preseribers of
`Controlled Substances
`
`BS, Pharmacy
`University of Colorado School of Pharmacy, Denver, Colorado
`
`PROFESSIONAL LICENSURE
`
`1989
`
`1987
`
`Registered Pharmacist, State of Illinois
`
`(License No. 051-037644)
`
`Registered Pharmacist, State of Colorado
`
`(License No. 12376)
`
`PAR1008
`
`CBM of US. Patent No. 7,668,730
`Page 1 of41
`
`
`
`Page 1 of 41
`
`

`

`Robert J. Valuck, Ph.D., R.Ph.
`
`Curriculum Vitae
`
`Page 2
`
`EMPLOYMENT EXPERIENCE
`
`A. Academic Appointments
`
`20] 1-present
`
`Professor (joint appointment), Department of Epidemiology, Colorado School
`of Public Health
`
`2009-present
`
`Professor (joint appointment), Department of Family Medicine, University of
`Colorado Denver, School of Medicine
`
`2008-present
`
`Professor, Department of Clinical Pharmacy, University of Colorado Denver,
`School of Pharmacy
`Member, Graduate Faculty, Department of Pharmaceutical Sciences, University
`of Colorado Denver
`
`Currenl leaching assignments:
`
`
`PhD. Cuniculum in Pharmaceutical Outcomes Research
`
`I PHSC7615/EPID7615: Pharmacoepidemiology (Course Director, Instructor)
`I PHSC7570: Special Topics in Pharmaceutical Outcomes Research (Instructor)
`I PHSC7710: Research Practicum (Course Director, Instructor)
`
`PharmD. Curriculum {Entg-level program)
`I PHRD6400: Clinical Biostatistics (Course Director, Instructor)
`I PHRD4550/PRMD6000: Ethics in the Health Professions (Group facilitator)
`I PHRD6150: Professional Skills Development IV (Guest lecturer)
`
`2006-present
`
`Guest Lecturer, Department of Preventive Medicine and Biometrics, University of
`Colorado School of Medicine (topic: Introduction to Pharmacoepidemiology)
`
`2001-2008
`
`1998—2003
`
`Associate Professor, Department of Clinical Pharmacy, University of Colorado
`Denver, School of Pharmacy, and Member, Graduate Faculty, Department of
`Pharmaceutical Sciences, University of Colorado Denver
`
`Guest Lecturer, Primary Care Residency Program, University of Colorado School
`of Medicine (topic: Critical Appraisal of Published Drug Studies).
`
`1996-present
`
`Member, Graduate College, University of Colorado Denver
`
`1994-2001
`
`Assistant Professor, Department of Pharmacy Practice, University of Colorado
`Denver, School of Pharmacy, and Member, Graduate Faculty, Department of
`Pharmaceutical Sciences, University of Colorado Denver
`
`PAR1008
`
`CBM of US. Patent No. 7,668,730
`Page 2 of 41
`
`
`
`Page 2 of 41
`
`

`

`Robert J. Valuck, Ph.D., R.Ph.
`
`Curriculum Vitae
`
`Page 3
`
`1994—2000
`
`Previous courses taught at UCHSC School of Pharmacy:
`
`Ph.D. Curriculum in Pharmaceutical Outcomes Research
`
`I Research Methods for Pharmaceutical Outcomes Research (Instructor)
`I Data Analysis for Pharmaceutical Outcomes Research (Instructor)
`I Database Research Methods (Instructor)
`
`PharmD. Curriculum (Entry-level program)
`I Evidence-based Pharmacy Practice (Course Director, Instructor)
`I Introduction to Clinical Research Methodology I and II (Instructor)
`
`
`B. 8., Pharmacy Curriculum
`I Pharmacy and Health Care (instructor)
`I Pharmacy Systems and Drug Use Management (Course Director, Instructor)
`I Pharmacy Law and Professional Ethics (Course Director, Guest lecturer)
`
`B. Graduate Research Assistantships
`
`1991-1994
`
`Graduate Research Assistant, UIC College of Pharmacy
`I "Factors Influencing Prescribing Decisions in a Managed Care Setting" (co-Investigator)
`I "Meta-Analysis: Effects of Drug Therapy on Patients’ Quality of Life (co-Investigator)
`I ”Development and Validation of Behaviorally-Anchored Rating Scales for Student
`Evaluation of Pharmacy Instruction" (Project Director)
`I "Readership and Journal Preferences of Pharmacists in Illinois" (co-PI)
`
`C. Consulting (past five years’ activity only)
`
`H. Lundbeck A] S
`
`Forest Research Institute, Inc.
`
`Eli Lilly and Company, Inc.
`Medical-legal consulting (various attorneys, law firms)
`
`2008-2010
`2008-2010
`
`2005-2010
`
`2004-present
`
`D. Professional
`
`1993 - 1994
`1990 - 1993
`1989 - 1993
`1988 - 1989
`1987 - 1988
`1987
`
`Clinical Pharmacist (home health care), Cardiac Alliance, Northbrook, Illinois
`Clinical Pharmacist (home health care), Critical Care America, Elk Grove, Illinois
`Registry Pharmacist, Pharmstaff, Inc., Chicago, Illinois
`Decentralized Pharmacist, University Hospital, Denver, Colorado
`Pharmacy Manager, Watson’s Tabor Center Drug, Denver, Colorado
`Pharmacist, Hodel’s Drug, Denver, Colorado
`
`PAR1008
`
`CBM of US. Patent No. 7,668,730
`Page 3 of 41
`
`
`
`Page 3 of 41
`
`

`

`Robert J. Valuck, Ph.D., R.Ph.
`
`Curriculum Vitae
`
`Page 4
`
`GRANTSMANSHIP
`
`
`A. Funded Grants & Contracts
`
`2013
`
`2012
`
`2012
`
`2011
`
`2011
`
`2010
`
`2010
`
`“Population-based Pharrnacosurveillance of Anticholinergic and
`Polypharrnacologic Toxicity Employing Computational Molecular Modeling
`Techniques.” Co-PI (0.10 FTE X 1 year [Year 2]), with Vaughn Culbertson (Co-
`PI) and others. Funded by the Skaggs Scholars Program, University of Colorado
`Skaggs School of Pharmacy and Pharmaceutical Sciences. Funding amount:
`$75,000. Funding period: 7/13 - 6/15.
`
`“Comparative Effectiveness Research through Collaborative Electronic Reporting
`(CER-squared)” Co-Investigator and Pharmacoepidemiology Lead (0.10 FTE x 5
`years), with M Wasserman and A Fiks (Co-Principal Investigators) and others.
`Funded jointly by HRSA and MCHB (HRSA MCHB R40MC24943 grant).
`Funding amount: $5.0 Million. Funding period: 9/12 - 8/17.
`
`“Not What the Doctor Ordered: Exploring Errors Between EHR Prescription and
`Pharmacy Fulfillment.” Co-Investigator (0.08 FTE X 1 year), with Gerry Pulver
`(Principal Investigator) and others. Funded by: The Doctors Company Foundation.
`Funding amount: $68,838. Funding period: 10/12 — 09/13.
`
`“Enhancing Fulfillment Data in Community Practices for Clinical Care and
`Research.” Co—Investigator (0.08 FTE X 2 years), with Michael Kahn, M.D.
`(Principal Investigator) and others. Funded by: Agency for Healthcare Research
`and Quality (AHRQ), National Institutes of Health (NIH). Budget: $190,455.
`Funding period: 9/11 — 12/13.
`
`“Colorado Evidence-based Retrospective Drug Utilization Review Program.”
`Co-Principal Investigator and Analytic Lead (0.10 FTE X 1 year), with Robert
`Page, Pharrn.D. (Co-PI and Clinical Lead) and Gina Moore, PharmD. (Co-PI
`and Education Lead). Funded by: Colorado Department of Health Care Policy
`and Financing (HCPF). Budget: $167,923. Funding period: 07/11 — 06/12.
`
`“Scalable Architecture for Federated Therapeutic Inquiries Network (SAFTINet).”
`Co-Investigator (0.10 FTE X 3 years), with Lisa Schilling, M.D. (Principal
`Investigator) and others. Funded by: Agency for Healthcare Research and
`Quality (AHRQ), National Institutes of Health (NIH). Budget: $2,460,053.
`Funding period: 10/10 — 09/13.
`
`“Colorado CER and Safety Scholars Program: Mental Health, CVD, and Methods.”
`(K12 training program grant). K12 trainee Mentor (0.10 FTE X 3 years) with Anne
`Libby, Ph.D. (Principal Investigator) and others. Funded by: Agency for Healthcare
`Research and Quality (AHRQ), National Institutes of Health (NlH). Budget:
`$1,500,000. Funding period: 07/10 — 06/13.
`
`PAR1008
`
`CBM of US. Patent No. 7,668,730
`Page 4 of 41
`
`
`
`Page 4 of 41
`
`

`

`Robert J. Valuck, PhD., R.Ph.
`
`Curriculum Vitae
`
`Page 5
`
`2009
`
`2009
`
`2009
`
`2009
`
`2008
`
`2008
`
`2007
`
`2007
`
`“A Cardiovascular Risk Reduction Learning Community in DARTNet.” Co—
`Investigator (0.10 FTE X 2 years), with Karl Hammerrneister, MD. (Principal
`Investigator). Funded by: National Heart, Lung, and Blood Institute (NHLBI),
`National Institutes of Health (NIH), ARRA Challenge Grants program. Budget:
`$1,066,415. Funding period: 09/09 — 08/11.
`
`“Predicting the Development of Opioid Abuse or Dependence.” Consultant (0.03
`FTE), with Bryan Cochran, University of Montana (Principal Investigator) and
`others. Funded by: National Institute on Drug Abuse (NIDA), National Institutes
`of Health (NIH). Budget: $100,000. Funding period: 07/09 — 06/11.
`
`“Sedative Hypnotic Use by the Mentally III: A Medicaid Prescription Policy
`Study.” Co—Investigator (0.05 FTE), with Judy Zerzan, MD. (Principal
`Investigator). Funded by: National Institute of Mental Health (NIMH), National
`Institutes of Health (NIH). Budget: $833,534. Funding period: 07/09 - 06/ 12.
`
`“Comparative Effectiveness and Safety of Depression Treatments in DARTNet
`Primary Care Practices.” Co—Investigator and Director of Research Core (0.20
`FTE X 19 months), with David West, PhD. (PI), Wilson Pace, MD. (Task Order
`Leader) and others. Funded by: Agency for Healthcare Research and Quality
`(AHRQ), National Institutes of Health (NIH), DECIDE Network Contract Number
`HHSA29020050037I—TO4. Budget: $1,600,000. Funding period: 04/09 - 10/10.
`
`“Consortium for the Study of Drug Safety.” Co-Investigator (0.10 FTE X 4 years),
`with Robert Gibbons, Ph.D., University of Chicago (Principal Investigator).
`Funded by: National Institute of Mental Health (NIMH), National Institutes of
`Health (NIH). Budget: $223,174 (subcontract to Dr. Valuck at UCDenver).
`Funding period: 7/08 - 6/13 (5 year grant, subcontract runs for years 2-5).
`
`“Antidepressant Drug Exposure and Risk of Suicide Attempt: A Focus on Newer
`Agents.” Principal Investigator (0.60 FTE X 9 months). Funded by: Eli Lilly and
`Company. Budget: $523,895. Funding period: 05/08 - 09/10.
`
`“The Distributed Ambulatory Research in Therapeutics Network (DARTNet).”
`Co-Investigator and Director of Research Core (0.20 FTE X 16 months), with
`David West, PhD (Principal Investigator), Wilson Pace, MD (Task Order Leader)
`and others. Funded by: Agency for Healthcare Research and Quality (AHRQ),
`National Institutes of Health (NIH), DECIDE Network Contract Number
`HHSA29020050037I—TO2. Budget: $1,350,000. Funding period: 09/07 - 04/09.
`
`“Impact of Antidepressant Discontinuation on Risk of Suicide Attempt.” Principal
`Investigator (0.20 FTE X 14 months). Funded by: American Foundation for
`Suicide Prevention (AF SP), Distinguished Investigator Grants Program. Budget:
`$99,710. Funding period: 07/07 - 08/08.
`
`PAR1008
`
`CBM of US. Patent No. 7,668,730
`Page 5 of 41
`
`
`
`Page 5 of 41
`
`

`

`Robert J. Valuck, Ph.D., R.Ph.
`
`Curriculum Vitae
`
`Page 6
`
`2006
`
`2006
`
`2005
`
`2005
`
`2005
`
`2004
`
`2003
`
`2003
`
`“Evaluating the Impact of Drug Warnings and Consensus Recommendations for
`Metabolic Testing for Patients Receiving Atypical Antipsychotic Drugs: A Multi-
`State Medicaid Claims Study.” Co—Investigator (0.15 FTE X 4 months) with
`Elaine H. Morrato, Dr.PH. (Principal Investigator). Funded by: Pfizer, Inc.
`Budget: $89,663. Funding period: 12/06 - 11/07.
`
`“Effect of the FDA Black Box Warning (Antidepressants and Suicidality) on
`Patterns of Depression Care in the US. Managed Care Population.” Principal
`Investigator (0.68 FTE X 8 months). Funded by: Eli Lilly and Company.
`Budget: $249,417. Funding period: 4/06 - 11/06.
`
`“An Observational Study of the Medical Management of Congestive Heart
`Failure and the Effectiveness of Isosorbide Dinitrate and Hydralazine.” Project
`Pharmacoepidemiologist (no salary), with Karl Hammerrneister, M.D. (PI) and
`others. Funded by: Agency for Healthcare Research and Quality (AHRQ), National
`Institutes of Health. Budget: $200,000. Funding period: 09/05 - 12/06.
`
`“The Colorado DEcIDE (CO—DECIDE) Center.” Co—Investi gator (percent effort
`based on specific Task Orders), with John Steiner, M.D. (Principal Investigator).
`Funded by: Agency for Healthcare Research and Quality (AHRQ), National
`Institutes of Health (NIH). Budget: TBD (based on specific Task Orders).
`Funding period: 9/05 - 8/10.
`
`“Effect of Tier Placement of Duloxetine on Medication Adherence, Healthcare
`
`Utilization, and Expenditures.” Co-Investi gator (0.05 FTE) with Kavita Nair,
`PhD. (Principal Investigator). Funded by: Eli Lilly and Co. Budget: $77,415.
`Funding period: 9/05 - 6/06.
`
`"Planning Grant for a Prescription Drug Monitoring Program in Colorado." Co-
`Principal Investigator (no salary offset), with Jody Gingery, M.Ed., RN, and Susan
`Warren, J .D., M.P.H. Funded by: US. Department of Justice, Office of Justice
`Programs (OJP), Bureau of Justice Assistance (BJA). Budget: $50,000. Funding
`period: 07/04 — 06/05.
`
`"Atypical Antipsychotic Treatment Patterns in a Multi-state Medicaid Population."
`Principal Investigator (0.30 FTE), With various co-investigators. Funded by:
`Janssen Pharrnaceutica LP. Budget: $129,780. Funding period: 01/04 - 12/05.
`
`"The Impact of Cost Sharing on Medication Compliance, Medical Utilization,
`and Patient Satisfaction." Co—investigator (0.10 FTE), with Patrick Sullivan, PhD.
`(Principal Investigator). Funded by: Pfizer, Inc. Budget: $98,826. Funding period:
`12/03 - 09/04.
`
`PAR1008
`
`CBM of US. Patent No. 7,668,730
`Page 6 of 41
`
`
`
`Page 6 of 41
`
`

`

`Robert J. Valuck, Ph.D., R.Ph.
`
`Curriculum Vitae
`
`Page 7
`
`2003
`
`"The Societal Cost of GI Adverse Events Associated with Current Utilization of
`
`Aspirin and NSAle in the United States." Co—investigator (0.08 FTE), with
`Patrick Sullivan, PhD. (Principal Investigator). Funded by: Pfizer, Inc. Budget:
`$49,354. Funding period: 12/03 — 07/04.
`
`2003
`
`2003
`
`2003
`
`2002
`
`2000
`
`2000
`
`2000
`
`1999
`
`1999
`
`"Demonstrating a Return on Investment for Micromedex Products: A Case Study.
`Co-Principal Investigator (0.05 FTE), with Kavita Nair, PhD. Funded by:
`Thomson MicromedeX, Inc. Budget: $29,792. Funding period: 10/03 — 04/04.
`
`"Incidence, Treatment Patterns, and Costs of SRI-related Side Effects." Principal
`Investigator (0.50 FTE), with Patrick Sullivan, PhD. and Joseph Saseen, PharmD.
`(co—investigators). Funded by: Forest Laboratories, Inc. Budget: $321,706.
`Funding period: 03/03 — 12/03.
`
`"Absorption of Oral Vitamin B-12 in Older Outpatients with Omeprazole-induced
`Gastric Acid Suppression." Co-investigator/Statistician (0.0] FTE), with J. Mark
`Ruscin, PharmD. (Principal Investigator). Funded by: University of Colorado
`Center for Human Nutrition. Budget: $44,663. Funding period: 01/03 — 12/04.
`
`"Incidence of Drug Induced Liver Injury." Co-Investigator (0.05 FTE), with K.
`Arnold Chan, MD. (Principal Investigator), and Marsha A. Raebel, PharmD.
`(local site PI). Funded by: National Institute of Diabetes & Digestive & Kidney
`Diseases (NIDDKD), National Institutes of Health. Budget: $120,939 (site
`portion), $14,136 subcontract to Dr. Valuck. Funding period: 11/02 - 9/04.
`
`"Residency in Managed Care Pharmaceutical Outcomes Research." Co—Preceptor
`(no salary offset). Training Site: Anthem—Blue Cross Blue Shield. Funded by:
`Pfizer, Inc., and Pharrnacia, Inc. Budget: $30,837. Funding period: 2000 — 01.
`
`"Retrospective Claims Database Analysis of Cholesterol Management in a
`Managed Care Population." Principal Investigator (0.20 FTE). Funded by the
`Quality Care Research Fund. Budget: $57,980. Funding period: 12/00 — 5/01.
`
`"Evaluating the Effects of Multi-tiered Pharmacy Benefits on Patient Purchasing
`Behavior." Co-Investigator (0.20 FTE). Funded by the Quality Care Research
`Fund. Budget: $198,103. Funding period: 9/00 — 6/02.
`
`"Patient Profiling and Provider Feedback to Reduce Adverse Drug Events" (SAF
`98144-1). Consultant. Funded by: VA Health Services Research & Development
`(HSR&D) Program. Budget: $540,000. Funding period: 1/00 - 2/02.
`
`"Colorado Medicaid Antiviral Drug Use Review (DUR) Project." Co—Principal
`Investigator (0.05 FTE). Funded by: Glaxo Wellcome, Inc. Budget: $5,000.
`Funding period: 12/99-5/00.
`
`PAR1008
`
`CBM of US. Patent No. 7,668,730
`Page 7 of 41
`
`
`
`Page 7 of 41
`
`

`

`Robert J. Valuck, Ph.D., R.Ph.
`
`Curriculum Vitae
`
`Page 8
`
`1999
`
`1999
`
`1999
`
`1999
`
`1998
`
`1998
`
`1997
`
`1997
`
`1997
`
`1997
`
`1996
`
`"Patterns of SSRI Prescribing and Use in a Managed Care Population." Principal
`Investigator (0.25 FTE). Funded by: Pharrnacia & Upjohn. Budget: $44,500.
`Funding period: 12/99 — 5/00.
`
`Continuing Education program development contract: "Urinary Incontinence and
`Overactive Bladder: A Comprehensive Approach." Program Chair. Funded by:
`Pharrnacia & Upjohn. Budget: $9,280. Funding period: 9/99 - 12/99.
`
`"Development and Testing of CliniMED Computer Software System.” Principal
`Investigator (no salary offset). Funded by: Pharrnacia & Upjohn. Budget:
`$58,000. Funding period: 6/99 - 5/01.
`
`"Use of Selective Serotonin Reuptake Inhibitors in Veterans Affairs Medical
`Centers." Co-Principal Investigator (0.05 FTE). Funded by: Pharrnacia &
`Upjohn. Budget: $14,500. Funding period: 6/99 - 11/99.
`
`"Development of a Clinical Decision Support System for Hypertension Patients in
`the VA Medical System." Co—Principal Investigator (no salary offset). Funded by:
`Astra Merck, Inc. Budget: $13,900. Funding period: 7/98 - 6/99.
`
`"Treatment Patterns in a Medicaid HIV Population: Guidelines Achievement and
`Health Systems Implications." Co-Principal Investigator (no salary offset). Funded
`by: Glaxo Wellcome, Inc. Budget: $50,000. Funding period: 3/98 - l2/98.
`
`"H. Pylori Treatment Patterns in the Colorado Medicaid Population." Co-
`Principal Investigator (no salary offset). Funded by Astra Merck, Inc. Budget:
`$8,900, Funding period: 1/98 - 12/98.
`
`"Protease Inhibitors: Patterns of Use, Therapy Conversion, and Adverse Events
`in the Colorado Medicaid Population." Principal Investigator (no salary offset).
`Funded by Agouron Pharrna. Budget: $6,055. Funding period: 12/97— 2/98.
`
`"Evaluation of In—Person Versus Computer—Mediated Small Group Learning in a
`Web-based Doctor of Pharmacy Class." Principal Investigator (no salary offset).
`Funded by the UCHSC Bridge to the Future Innovations in Education MiniGrant
`Program. Budget: $4,000. Funding period: 1997-1998.
`
`"Development of Drug Specifrc Drug-Drug Interaction D.U.R. Criteria." Principal
`Investigator (0.25 FTE). Funded by the United States Pharrnacopeial Convention
`(USP), Inc. Budget: $150,000. Funding period: 2/1/97 - 5/31/98.
`
`"Using Computerized Decision Support to Promote Adherence to
`Pharmacotherapy Guidelines for Drug Treatment of Hyperlipidemias in
`Veterans." Principal Investigator (no salary offset). Funded by Pharrnacia &
`Upjohn. Budget: $18,100. Funding period: 1996-1998.
`
`PAR1008
`
`CBM of US. Patent No. 7,668,730
`Page 8 of 41
`
`
`
`Page 8 of 41
`
`

`

`Robert J. Valuck, Ph.D., R.Ph.
`
`Curriculum Vitae
`
`Page 9
`
`1996
`
`1996
`
`1996
`
`1996
`
`1996
`
`1995
`
`1995
`
`1995
`
`1996
`
`"Serzone Drug Use Evaluation in the Colorado Medicaid Population." Principal
`Investigator (no salary offset). Funded by Bristol—Myers Squibb. Budget:
`$1,500. Funding period: 1996-1997.
`
`"Development and Implementation of a Web-Based Course in Evidence-Based
`Pharmacy Practice Within the PharmD. Program." Principal Investigator (no
`salary offset). Funded by the UCHSC Bridge to the Future Innovations in
`Education MiniGrant Program. Budget: $4,950. Funding period: 1996-1998.
`
`"The Effect of Clinical Pharmacy Services on Patient Care, Outcomes, and Costs
`in Two University Hospital Outpatient Clinics." Co-Investigator (no salary
`offset). Funded by the University Hospital Education and Research Committee
`Grants Program. Budget: $27,500. Funding period: 1996-1998.
`
`"Evaluating the Outcomes of Pharmaceutical Care Services in a Managed Care
`Setting." Co—Investigator (no salary offset). Funded by the Department of
`Pharmacy Practice, University of Colorado School of Pharmacy. Budget: $5,000.
`Funding period: 1996-1997.
`
`First Rocky Mountain Regional D.U.R. Symposium: "Drug Forrnularies -
`Implications for Access, Cost, and Quality of Care", Aug 23 -25, 1996. Program
`Organizer/Chair (no salary offset). Funded by: Astra-Merck. Budget: $37,500.
`
`"Colorado Medicaid Program Cost of Dispensing Study." Co-Principal
`Investigator (0.60 FTE). Funded by the State of Colorado, Department of Health
`Care Policy & Financing. Budget: $37,447. Funding period: 4/ 1-6/30, 1996.
`
`"Implementation of Pharmaceutical Care in Veterans Affairs Medical Centers
`Utilizing Managed Care Principles." Co-Investigator (0.15 FTE). Funded by the
`Department of Veterans Affairs Research Steering Committee and Pharmacia &
`Upjohn, Inc. Budget: $523,285. Funding period: 1996-1998.
`
`"Evaluation of a Heparin Titration Nomogram on Patient Outcomes at University
`Hospital (UH). " Co-Investigator (no salary offset). Funded by the UH Education
`and Research Committee. Budget: $17,500. Funding period: 1996-1999.
`
`"Using Computerized Decision Support to Promote Adherence to
`Pharmacotherapy Guidelines for Drug Treatment of Hyperlipidemias in
`Veterans." Principal Investigator (no salary offset). Funded by Pharmacia &
`Upjohn. Budget: $18,100. Funding period: 1996-1998.
`
`PAR1008
`
`CBM of US. Patent No. 7,668,730
`Page 9 of 41
`
`
`
`Page 9 of 41
`
`

`

`Robert J. Valuck, Ph.D., R.Ph.
`
`Curriculum Vitae
`
`Page 10
`
`
`B. Fellowship / Training support (for self and students/trainees/mentees)
`
`2009
`
`2008
`
`1994
`
`Colorado Clinical and Translational Science Institute (CCTSI) “Pharmaco—
`Epidemiology Training Program” seed funding, $34,000. Support for one trainee
`(Heather Orton, Ph.D.), and salary support for self for program development and
`mentorship (0.20 FTE X 3 months; equivalent to 0.05 FTE X 12 months).
`
`American Foundation for Pharmaceutical Education (AFPE) “Gateway to
`Research” Scholarship (for student mentee: Angela Luetters), 2008-2009, $5,000.
`
`American Foundation for Pharmaceutical Education (AFPE) "Springboard to
`Teaching" Fellowship (for self), 1994-1996, $15,000.
`
`1993
`
`Upjohn Company Clinical Research Grant, $1,500 (dissertation support, for self).
`
`PUBLICATIONS
`
`
`A. Articles
`
`Bronsert M.R., Henderson W.G., Valuck R., Hosokawa P., and Hammermeister K. Comparative
`Effectiveness of Antihypertensive Therapeutic Classes and Treatment Strategies in the
`Initiation of Therapy in Primary Care Patients: A Distributed Ambulatory Research in
`Therapeutics Network (DARTNet) Study. Journal of the American Board ofFamily
`Medicine 2013; 26(5):529-53 8.
`
`Davis L.A, Cannon G.W., Pointer L.F., Haverhals L.M., WolffR.K., Mikuls T.R., Reimold A.M.,
`
`Kerr GS, Richards J.S., Johnson D.S., Valuck R., Prochazka A., and Caplan L.
`Cardiovascular Events Are Not Associated with MTHFR Polymorphisms, But Are
`Associated with Methotrexate Use and Traditional Risk Factors in US Veterans with
`
`Rheumatoid Arthritis. Journal ofRheumatology 2013; 40(6):809-817.
`
`Czaja A.S., Valuck R.J., and Anderson H.D. Comparative Safety of Selective Serotonin
`Reuptake Inhibitors Among Pediatric Users With Respect to Adverse Cardiac Events.
`Pharmacoepia’emiology and Drug Safety 2013; 22(6):607-614.
`
`Slejko J .F., Libby A.M., Nair K.V., Valuck R.J., and Campbell JD. Pharrnacoeconomics and
`Outcomes Research Degree-granting PhD Programs in the United States. Research in
`Social and Administrative Pharmacy 2013; 9(1): 108-1 13 .
`
`PAR1008
`
`CBM of US. Patent No. 7,668,730
`Page 10 of41
`
`
`
`Page 10 of 41
`
`

`

`Robert J. Valuck, Ph.D., R.Ph.
`
`Curriculum Vitae
`
`Page 11
`
`Czaja AS, and Valuck R.J. Off-label Antidepressant Use in Children and Adolescents
`Compared with Young Adults: Extent and Level of Evidence. Pharmacoepidemiology
`andDrug Safety 2012; 21(9):997-1004.
`
`Valuck R.J., Anderson H.O., Libby A.M., Brandt E., Bryan C., Allen RR, Staton E.W., West
`DR, and Pace W.D. Enhancing Electronic Health Record Measurement of Depression
`Severity and Suicide Ideation: A Distributed Ambulatory Research in Therapeutics
`Network (DARTNet) Study. Journal of the American Board ofFamily Medicine 2012;
`25(5):582-593.
`
`Schumock G.T.; Stayner L.T., Valuck R.J., J00 M.J., Gibbons RD, and Lee T.A. Risk of
`Suicide Attempt in Asthmatic Children and Young Adults Prescribed Leukotriene-
`modifying Agents: A Nested Case-control Study. Journal ofAllergy and Clinical
`Immunology 2012; 130(2):368-375.
`
`Reiter PD; Wathen B.; Valuck R.J., and Dobyns E.L. Thrombosis Risk Factor Assessment and
`Implications for Prevention in Critically 111 Children. Pediatric Critical Care Medicine
`2012; 13(4):381-386.
`
`Hoffman D.A., DeBattista C., Valuck R.J., and losifescu D.V. Measuring Severe Adverse
`Events and Medication Selection Using a “PEER Report” for Nonpsychotic Patients: A
`Retrospective Chart Review. Neuropsychiatric Disease and Treatment 2012; 8:277-284.
`
`Schumock G.T., Gibbons R.D., Lee T.A., Joo M.J., Stayner LT, and Valuck R.J. The
`Association Between Leukotriene-Modifying Agents and Spontaneously Reported Suicide.
`Drug Information Journal 2012; 46:99- 106.
`
`Anderson H.D., Pace W.D., Libby, AM., West DR, and Valuck R.J. Rates of 5 Common
`Antidepressant Side Effects Among New Adult and Adolescent Cases of Depression:
`A Retrospective U.S. Claims Study. Clinical Therapeutics 2012; 34(1) :113-123.
`
`Shumock G., Gibbons R., Lee T., J00 M., Valuck R.J., and Stayner L. Relationship Between
`Leukotriene-modifying Agent Prescriptions Dispensed and Rate of Suicide Deaths by
`County in the US. Drug, Healthcare and Patient Safety 2011; 3: 1-6.
`
`Sanglier T.; Saragoussi D; lVlilea D.; Auray JP; Valuck R.J.; and Tournier M. Comparing
`Antidepressant Treatment Patterns in Older and Younger Adults: A Claims Database
`Analysis. JAm Geriatr Society (JAGS) 2011; 59(7): 1 197-1205.
`
`Shumock G., Lee T., J00 M., Valuck R.J., Stayner L., and Gibbons R. Association Between
`Leukotriene Modifying Agents and Suicide: What is the Evidence? Drug Safety 2011;
`34(7):533—544.
`
`PAR1008
`
`CBM of US. Patent No. 7,668,730
`Page 11 of41
`
`
`
`Page 11 of 41
`
`

`

`Robert J. Valuck, Ph.D., R.Ph.
`
`Curriculum Vitae
`
`Page 12
`
`Henderson KC, Hindman J., Johnson S.C., Valuck, R.J., and Kiser J.J. Assessing the
`Effectiveness of Pharmacy—Based Adherence Interventions on Antiretroviral Adherence in
`Persons with HIV. AIDS Patient Care and STDs 2011; 25(4):221-228.
`
`Morrato E..H, Druss B.G., Hartung D.M., Valuck R.J., Thomas D., Allen R., Campagna E., and
`Newcomer J.W. Small Area Variation and Geographic and Patient-specific Determinants
`of Metabolic Testing in Antipsychotic Users. Pharmacoepidemiology and Drug Safety
`2010; 19:1-10.
`
`Libby A.M., Pace W., Anderson H.O., Bryan C., Ellis S., Allen R.R., Brandt E., West D., and
`Valuck R.J. Comparative Effectiveness Research in DARTNet Primary Care Practices:
`Point of Care Data Collection on Hypoglycemia and Over-the-Counter and Herbal Use
`among Patients Diagnosed with Diabetes. Medical Care 2010; 48: S39-S44.
`
`Morrato E.H., Nicol G.E., Maahs D., Druss B.G., Hartung D.M., Valuck R.J., Campagna E.,
`and Newcomer J.W. Metabolic Screening in Children Receiving Antipsychotic Drug
`Treatment. Archives ofPediatric and Adolescent Medicine 2010; l64(4):344-351,
`
`Reiter; P.D., Huff, A.D, Knupp, K.G., and Valuck, R.J. Intravenous Levetiracetam in the
`Management of Acute Seizures in Children. Pediatric Neurology 2010; 43:117-121.
`
`Morrato E..H, Druss B., Hartung D.M., Valuck R.J., Allen R., Campagna E., and Newcomer
`J.W. Metabolic Testing Rates in 3 State Medicaid Programs After FDA Warnings and
`ADA/APA Recommendations for Second—Generation Antipsychotic Drugs. Archives of
`General Psychiatry 2010; 67(1): 17-24.
`
`Pace, W.D., Cifuentes, M., Valuck, R.J., et al. An Electronic Practice-Based Research Network
`
`for Observational Comparative Effectiveness Research. Annals ofInternal Medicine
`2009; 151:1-3.
`
`Valuck, R.J., Orton, H.D., and Libby, A.M. Antidepressant Discontinuation and Risk of Suicide
`Attempt: A Retrospective, Nested Case-Control Study. Journal of Clinical Psychiatry
`2009; 70(8): 1069-1077.
`
`Pace, W., West, D., Valuck, R., et a1. Distributed Ambulatory Research in Therapeutics Network
`(DARTNet): Summary Report. (Prepared by University of Colorado DEchE Center
`under contract number HHSA-29020050037I-T02). Rockville, MD: Agency for
`Healthcare Research and Quality (AHRQ), National Institutes of Health (NIH), July 2009.
`Available at: effectivehealthcare.ahrqgov/reports/final.cfm. [Peer-reviewed, published
`report of DEcIDE Center DARTNet grant]
`
`Libby, A.M., Orton, H.D., and Valuck, R.J. Persisting Decline in Depression Treatment After
`FDA Warnings. Archives of General Psychiatry 2009; 66(6):633-639.
`
`PAR1008
`
`CBM of US. Patent No. 7,668,730
`Page 12 of41
`
`
`
`Page 12 of 41
`
`

`

`Robert J. Valuck, Ph.D., R.Ph.
`
`Curriculum Vitae
`
`Page 13
`
`Hammermeister, K.E., Fairclough, D., Emsermann, C.B., Hamman, R., Ho, M., Phibbs, S.,
`Plomondon, M., Valuck, R., West, D., and Steiner, J .F. Effectiveness of Hydralazine/
`lsosorbide Dinitrate in Racial/Ethnic Subgroups with Heart Failure. Clinical
`Therapeutics 2009; 31 1632-643.
`
`Williams-Skipp, 0, Raman, T., Valuck, R.J., Watkins, H., Palmer, BE, and Scheinman, R.l.
`Unmasking of a Protective Tumor Necrosis Factor Receptor l—Mediated Signal in the
`Collagen—Induced Arthritis Model. Arthritis & Rheumatism 2009; 60:408—418.
`
`Morrato, EH, Newcomer, J .W., Allen, R., and Valuck, R.J. Prevalence of Baseline Serum
`
`Glucose and Lipid Testing in Users of Second—Generation Antipsychotic Drugs: A
`Retrospective, Population Based Study of Medicaid Claims Data. Journal of Clinical
`Psychiatry 2008; 69:316-322.
`
`Morrato, E.H., Libby, A.M., Orton, H.D., deGruy lll, F.V., Brent, D.A., Allen, R., and Valuck,
`R.J. Frequency of Provider Contact After FDA Advisory on Risk of Pediatric Suicidality
`with SSRIs. American Journal ofPsychiatry 2008; 165:42-50.
`
`Valuck, R.J., Libby; A.M., Benton; T., and Evans, D.L. A Descriptive Analysis of 10,000
`Suicide Attempters in United States Managed Care Plans, 1998-2005. Primary
`Psychiatry 2007; 14(11):52-60.
`
`Valuck, R.J., Morrato, E.H., Dodd, 8., Oderda, G., Haxby, D.G., and Allen, R. How Expensive
`is Antipsychotic Polypharmacy? Experience from Five US State Medicaid Programs.
`Current Medical Research and Opinion 2007; 23(10):2567-2576.
`
`Valuck, R.J., Libby, A.M., Orton, H.D., Morrato, EH, Allen, R., and Baldessarini, R.J.
`Spillover Effects on Treatment of Adult Depression in Primary Care After FDA Advisory
`on Risk of Pediatric Suicidality With SSRIs. American Journal ofPsychiatry 2007;
`164: 1 198—1205.
`
`McClure, D.L., Valuck, R.J., Glanz, M., Murphy, J .R., and Hokanson, J .E. Statin and
`Statin/Fibrate Use Were Significantly Associated With Increased Myositis Risk in a
`Managed Care Population. Journal of Clinical Epidemiology 2007; 60:812-818.
`
`Baldessarini, R.J., Tondo, L., Strombom, I.M., Dominguez, S., Fawcett, J., Licinio, J., Oquendo,
`M.A.; Tollefson, G.D., Valuck, R.J., and Tohen, M. Ecological Studies of Antidepressant
`Treatment and Suicidal Risks. Harvard Review ofPsychiatry 2007; 15(4): 133-145.
`
`Glassman, P.A., Balperio, P., Lanto, A., Simon, B., Valuck, R., Sayers, J., and Lee, M. The
`Utility of Adding Retrospective Medication Profiling to Computerized Provider Order
`Entry in an Ambulatory Care Population. Journal of the American Medical Informatics
`Association (JAMIA) 2007; 14:424-431.
`
`PAR1008
`
`CBM of US. Patent No. 7,668,730
`Page 13 of41
`
`
`
`Page 13 of 41
`
`

`

`Robert J. Valuck, Ph.D., R.Ph.
`
`Curriculum Vitae
`
`Page 14
`
`Reiter, P.D., Valuck, R.J., and Taylor, RS. Evaluation of Off-label Recombinant Activated
`Factor VII for Multiple Indications in Children. Clinical Applied Thrombosis and
`Hemostasis 2007; 13(3):233-240.
`
`Libby, A.M., Brent, D.A., Morrato, E..,H Orton, H.D., Allen, R., and Valuck, R.J. Decline in
`Treatment of Pediatric Depression After FDA Advisory on Risk of Suicidality with
`SSRIs. American Journal ofPsychiatry 2007 ; 164:884-891. [lead article]
`
`McClure, D.L., Valuck, R.J., Glanz, M., and Hokanson, J.E. Systematic Review and Meta-
`Analysis of Clinically Relevant Adverse Events from HIVIG CoA Reductase Inhibitor
`Trials Worldwide from l982-Present. Pharmacoepia’emiol Drug Safe. 2007; 16:132-143.
`
`Morrato, E.H., Dodd, S., Oderda, G., Habe, D.G., Allen, RR, and Valuck, R.J. on behalf of
`the Medicad Pharmacotherapy Research Consortium. Prevalence, Utilization Patterns,
`and Predictors of Antipsychotic Polypharrnacy: Experience in a Multistate Medicaid
`Population, 1998-2003. Clinical Therapeutics 2007; 29(1): 183-195.
`
`Reiter, P.D., Novak, K, Valuck, R.J., Rosenberg, AA, and Fish, D. Effect of a Closed Drug-
`Delivery System on the Incidence of Nosocomial and Catheter-Related Bloodstream
`Infections in Infants. Epidemiology and Infection 2006; l34(2):285-291.
`
`Davidson, J., Nair, K.V., Valuck, R.J., and Moore, G. Evidence—Based Medicine in the
`
`Pharmacy. Patient Safety & Quality Healthcare 2006; Mar/Apr: 46-49.
`
`Saseen J.J., Williams, S.A., Valuck, R.J., O’Donnell, J.C., and McDonough, K. The
`Performance Gap between C